Specifically, d-MAPPSTM Hypo-Osmotic Ophthalmic Solution contains interleukin 1 receptor antagonist (IL-1Ra), soluble receptors of tumor necrosis factor alpha (sTNFRI, sTNFRII), growth-related oncogene gamma (GRO-γ), fatty acid-binding protein 1 (FABP1), and platelet factor 4 (PF4), which alleviate eye inflammation, support tear stability, and prevent ocular surface epithelial damage, contributing to the enhanced repair and regeneration of the ocular surface epithelial barrier in DED patients [54]. This evidence concerns the gene PF4 and eye inflammation.